In the last trading session, 1.91 million Regenxbio Inc (NASDAQ:RGNX) shares changed hands as the company’s beta touched 1.09. With the company’s per share price at $9.61 changed hands at $1.25 or 14.95% during last session, the market valuation stood at $482.04M. RGNX’s last price was a discount, traded about -59.83% off its 52-week high of $15.36. The share price had its 52-week low at $5.03, which suggests the last value was 47.66% up since then.
Analysts gave the Regenxbio Inc (RGNX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.38. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended RGNX as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Regenxbio Inc’s EPS for the current quarter is expected to be -1.05.
Regenxbio Inc (NASDAQ:RGNX) trade information
Instantly RGNX was in green as seen at the end of in last trading. With action 8.59%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 24.32%, with the 5-day performance at 8.59% in the green. However, in the 30-day time frame, Regenxbio Inc (NASDAQ:RGNX) is 32.73% up.
The consensus price target for the stock as assigned by Wall Street analysts is 27, meaning bulls need an upside of 64.41% from its current market value. According to analyst projections, RGNX’s forecast low is 24 with 30 as the target high. To hit the forecast high, the stock’s price needs a -212.17% plunge from its current level, while the stock would need to soar -149.74% for it to hit the projected low.
Regenxbio Inc (RGNX) estimates and forecasts
Year-over-year growth is forecast to reach 303.06% up from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 40.87M. 9 analysts are of the opinion that Regenxbio Inc’s revenue for the current quarter will be 110.02M. The company’s revenue for the corresponding quarters a year ago was 22.3M and 24.2M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 83.30%. The estimates for the next quarter sales put growth at 354.69%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -12.18%. The 2025 estimates are for Regenxbio Inc earnings to increase by 93.72%, but the outlook for the next 5-year period is at 23.05% per year.
RGNX Dividends
Regenxbio Inc is expected to release its next quarterly earnings report in July.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 10.1061% or 5.11 million shares worth $59.83 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were JPMorgan Trust II-JPMorgan Small Cap Growth Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 1.98 shares estimated at $18.99 million under it, the former controlled 3.94% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.79% of the shares, roughly 1.4 shares worth around $13.46 million.
